Not interested in raking leaves? Brunch isn’t for another couple of hours? The kids are busy doing their own thing? Why not take a few minutes to catch up, then? And whatever you wind up doing later, we hope you enjoy your day…

Glaxo is suing Abbott over the price of its Norvir AIDS drug. Glaxo claims Abbott raised the price on the med, which boosts the effectiveness of other protease inhibitors, without increasing the price of Kaletra, which includes Norvir. The higher cost kept Norvir from being used with other drugs, including Glaxo’s Lexiva, at a competitive price, Bloomberg News writes. The lawsuit, which was filed Friday, is the latest against Abbott after the price was quadrupled in 2003. Patients and retailers also have sued. Abbott has repeatedly argued the the price was raised to reflect Norvir’s role as a boosting agent instead of a standalone drug, but Glaxo says Abbott just wanted to direct sales to Kaletra.

Talks between public health officials and drugmakers over a deal to ensure that poor countries can receive meds at affordable prices ended inconclusively on Saturday, Reuters reports. The Geneva meeting, sponsored by the United Nations’ World Health Organisation, was suspended after delegates exhausted the six days allotted for negotiations and agreed to meet again in late April. The goal is to produce guidelines that would encourage R&D of affordable meds to treat diseases prevalent in poor countries while respecting intellectual property rights. Pharma has condemned the WHO draft plan and richer countries home to much of the global drug industry remain cool. But health advocates, including aid agency Doctors Without Borders, say drug development for poor countries is lacking.

As MRSA becomes more widespread, the FDA and industry are moving faster to combat superbugs, in what could be a multibillion-dollar market for tests, drugs and devices, The Chicago Tribune writes. The latest sign came Friday when the agency approved a specially coated device that hospitals can use to prevent the deadly staph infection from entering the bloodstream, and the FDA says it’s trying to speed the review process for devices. “This is becoming more of an issue, so we are developing guidance on it so when manufacturers submit information on their device it is appropriate information for the types of things we want to look at,” Bill Maloney, a physicist at the FDA who reviewed an infection-resistant breathing tube that was approved last week.

After Pfizer scrapped Exubera, a move taken after a colossal failure in design and marketing, a huge question mark hovers over the future of insulin inhalers. But Novo Nordisk, which is the world’s biggest supplier of insulin, is adamant that there is still reason to proceed. “It’s a niche product but we believe there is a rational argument for developing it,” Lars Rebien Sorensen, the ceo tells The Times of London. “There’s going to come a time when the right concept has been designed and we hope it will be one of ours. We think if anyone can do this, we can do it, even better than Pfizer. We’re the biggest pharmaceutical company in insulin and we are spending a lot of money on it; we would like to see some of that money being returned. Of course, (the withdrawal of Exubera) is causing us to reevaluate our assumptions but we are continuing.”